- Direction
- Deteriorating
- Own history
- —
- Peers
- 82th
- Persistence
- EMERGING
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTBeta Bionics, Inc.'s latest supported as-filed period reports revenue of $35.5M; gross margin moved 524 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 6.41% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -34.61% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 30.28% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 64.70% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 57.26% · CORE
Level · gp.fundamentals.operating_margin
Raw value -74.94% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 30.3%; Operating margin moved 1241 bp lower; Operating income decreased 56.1%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 37.8%; Operating margin moved 562 bp higher; Operating income decreased 28.7%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 37.8%; Operating margin moved 562 bp higher; Operating income decreased 28.7%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 38.1%; Inventory / revenue moved 17 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 77.5%; Capex / revenue moved 170 bp higher.
2 evidence-backed componentsFree-cash-flow proxy changed -45.5% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
BBNX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002048500-26-000015SEC ↗4Oct 28, 2026Period Oct 26, 20260002048497-26-000023SEC ↗10-QOct 27, 2026Period Sep 30, 20260001674632-26-000003SEC ↗8-KOct 27, 2026Period Oct 27, 20260001171843-26-006856SEC ↗4Oct 16, 2026Period Oct 14, 20260002048497-26-000021SEC ↗4Oct 5, 2026Period Oct 1, 20260002048497-26-000018SEC ↗4Sep 23, 2026Period Sep 22, 20260002048467-26-000007SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 27, 2026Filed Oct 29, 2026 | Mensinger MikeChief Product Officer | Open Market SaleDirect | 2,650 | $22 | $58,300 | Form 4 ↗ |
| Oct 26, 2026Filed Oct 28, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 821 | $20 | $16,420 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 16, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 775 | $17 | $13,446 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 5, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 370 | $19 | $7,015 | Form 4 ↗ |
| Sep 22, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 33.73% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 18.91% · OPTIONAL
Operating income changed -56.1% from the comparable as-filed period.
Operating cash flow changed -40.8% from the comparable as-filed period.
Operating income changed -28.7% from the comparable as-filed period.
Net income changed -38.7% from the comparable as-filed period.
Net income changed -71.4% from the comparable as-filed period.
Gross margin changed +524 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002048497-26-000016| Jones ChristyDirector |
| Open Market SaleDirect |
| 6,430 |
| $23 |
| $147,890 |
| Form 4 ↗ |
| Sep 16, 2026Filed Sep 17, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 30,779 | $20 | $619,640 | Form 4 ↗ |
| Sep 14, 2026Filed Sep 15, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 775 | $16 | $12,028 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 18, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect · amended | 35,994 | $18 | $664,550 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 10, 2026 | Hopman MarkChief Commercial Officer | Open Market SaleDirect | 36,870 | $18 | $680,723 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 4, 2026 | Saint SeanPresident & CEO | Open Market SaleDirect | 5,641 | $20 | $113,259 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Mensinger MikeChief Product Officer | Open Market SaleDirect | 4,375 | $19 | $83,620 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Open Market SaleDirect · amended | 4,896 | $17 | $83,381 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Option ExerciseDirect · amended | 4,896 | $5 | $24,970 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Option ExerciseDirect · amended | 4,896 | $0 | $0 | Form 4 ↗ |
| Jun 26, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Open Market SaleDirect · amended | 5,104 | $17 | $87,006 | Form 4 ↗ |
| Jun 26, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Option ExerciseDirect · amended | 5,104 | $0 | $0 | Form 4 ↗ |
| Jun 26, 2026Filed Jul 2, 2026 | Feider StephenChief Financial Officer | Option ExerciseDirect · amended | 5,104 | $5 | $26,030 | Form 4 ↗ |